医保创新药舒沃替尼获江苏省科技进步奖一等奖

Core Insights - The innovative drug Shuwotini tablets, which targets a rare mutation in non-small cell lung cancer, has won the first prize in Jiangsu Province's Science and Technology Progress Award, highlighting its significant breakthrough in original innovation and clinical application [1] - Shuwotini tablets are the first and only drug approved for the EGFR 20 insertion mutation, receiving market approval in China in August 2023 and subsequently being included in the national medical insurance directory, significantly reducing patient costs [1] - The award recognizes the project's contributions to technological innovation and its impact on economic and social development, emphasizing the comprehensive strength of the research and development company in key technology breakthroughs and results transformation [1] Company and Industry Developments - The company, Dizhe Pharmaceutical, aims to continue addressing unmet clinical needs through technological innovation, accelerating the delivery of globally competitive original innovations to benefit patients worldwide [2] - The drug is expected to gain international recognition, as it was approved by the U.S. FDA in 2025, marking it as the first independently developed innovative drug from China to be approved in the U.S. and included in the National Comprehensive Cancer Network guidelines for non-small cell lung cancer [1]